IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v
NEPA-22-01
Phase 3 small_molecule active
Quick answer
IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v for Chemotherapy-induced nausea and vomiting is a Phase 3 program (small_molecule) at Helsinn Birex Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Helsinn Birex Pharmaceuticals Ltd
- Indication
- Chemotherapy-induced nausea and vomiting
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active